Evidence Central | Interferon in relapsing‐remitting multiple sclerosis

Download the app!

INSTALL

Interferon in relapsing‐remitting multiple sclerosis

57 results

1 - 57

Interferon in relapsing‐remitting multiple sclerosis
- Abstract
- Reviewer's Conclusions
Interferon in relapsing-remitting multiple sclerosis
- Evidence Summaries
- References
Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
- Abstract
- Reviewer's Conclusions
alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
- Abstract
- Reviewer's Conclusions
Alemtuzumab more effective than interferon for multiple sclerosis
- Clinical Question
- Bottom Line
- Reference
Mycophenolate mofetil for relapsing-remitting multiple sclerosis: Cochrane systematic review
- Abstract
- Summary
- Reviewer's Conclusions
Daclizumab for relapsing remitting multiple sclerosis
- Abstract
Multiple sclerosis (MS)
- Treatment
Statins for multiple sclerosis
- Evidence Summaries
Alemtuzumab for multiple sclerosis
- Abstract
- Reviewer's Conclusions
Natalizumab for relapsing remitting multiple sclerosis
- Evidence Summaries
Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta‐analysis
- Abstract
Fingolimod for relapsing‐remitting multiple sclerosis
- Abstract
- Reviewer's Conclusions
Azathioprine for people with multiple sclerosis
- Abstract
- Reviewer's Conclusions
Interferon beta for secondary progressive multiple sclerosis
- Evidence Summaries
Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis
- Abstract
Fingolimod for relapsing-remitting multiple sclerosis
- Evidence Summaries
Ocrelizumab for multiple sclerosis
- Abstract
- Reviewer's Conclusions
Interferon Beta for Primary Progressive Multiple Sclerosis
- Abstract
Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis
- Abstract
Interferon beta for secondary progressive multiple sclerosis
- Abstract
Statins for multiple sclerosis: Cochrane systematic review
- Summary
Alemtuzumab for multiple sclerosis
- Evidence Summaries
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis (RRMS): a network meta-analysis
- Evidence Summaries
Rituximab for relapsing-remitting multiple sclerosis: Cochrane systematic review
- Abstract
Natalizumab for relapsing remitting multiple sclerosis
- Abstract
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis
- Abstract
Laquinimod for multiple sclerosis: Cochrane systematic review
- Abstract
Teriflunomide for multiple sclerosis
- Abstract
Dimethyl fumarate for multiple sclerosis: Cochrane systematic review
- Abstract
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis
- Abstract
Natalizumab for multiple sclerosis
- Abstract
1 - 57 of 57 records

Log in to Evidence Central

Contact Support

If you need further assistance, please contact Support.

unboundmedicine.com/support
support@unboundmedicine.com
610-627-9090(Monday - Friday, 9 AM - 5 PM EST.)

Password reset sent

Username sent

A Evidence Central subscription is required to

Already have an account?